Grants
Awarded Grants
2021-2025 Trajectories of Psychosocial and Functional Outcomes among Non-Hodgkin Lymphoma (NHL) Survivors, Project Grant for Canadian Institutes of Health Research.
PI: Lisa Chodirker, Kelly Davison. John G. Kuruvilla, Christine Maheu, Samantha Mayo, Lee Mozessohn
Co-Investigators: Eshetu Getachew Atenafu,
$65,025
2020-2022 CIHR, Clonal Stromapoiesis and BM microenvironment in leukeumias and HCT
$200,000 - PI - Chodirker, Lisa - Atenafu; CO-I - Eshetu Getachew
SAMBA, Detecting and monitoring molecular residual disease (MRD) in high-risk melanoma patients through novel circulating tumor DNA (ctDNA) profiling technologies, Catalyst Grant
$100,000 CAD - PI - Anna Spreafico; Co-I - Sareh Keshavarzi
2015 Molecular characterization and behaviour of tumors arising in patients taking 5-alpha reductase inhibitors, Movember Discovery Grant Application
PI - Robert J. Hamilton; Co-I - Eshetu Atenafu
2015-2016 Applying radiomics to predict pathology of residual retroperitoneal nodal masses in metastatic germ cell tumors following platinum based chemotherapy
PI: Jeremy Lewin, Philippe Bedard, Princess Margaret Cancer Centre
Co-Investigator: Eshetu Atenafu, M.Sc., Pstat , Senior Biostatistician
2010-2012 CCSRI, PI Forsyth, Peter, Wang, L. et al: Phase I pharmacodynamic and “high content” study of the gamma-secretase inhibitor RO4929097 in patients with recurrent malignant gliomas (MGs) targeting p75NTR to inhibit brain tumour initiating cells (BTICs) and recurrent invasive gliomas
2019-2022 CIHR, Canadian Institutes of Health Research
Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer
$544,119 – PI –S Sridhar;Co-I – W Xu
2019-2023 CIHR, Canadian Institutes of Health Research
Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer
$750,000 – PI – W Xu, G Yousef, N Fleishman; Co-I – L Klotz
2019-2023 CIHR, Canadian Institutes of Health Research
Genomics-based radiosensitization for HPV-negative squamous cell carcinoma of the aerodigestive tract
$ 757,352 – PI – S Bratman; Co-I - W Xu
2018-2021 Prostate Cancer Canada
Combination of subpathology and noncoding RNA: integrating outcome prediction and treatment individualization for intermediate-risk prostate cancer
$1,499,250 – PI – Housheng He; Co-I - W Xu
2018-2022 CIHR, Canadian Institutes of Health Research
Early detection of cancer in high-risk patients through profiling of circulating tumour DNA
$1,977,525 – PI - T Pugh; Co-I - W Xu
2018-2021 Princess Margaret Cancer Centre Foundation
Artificial Intelligence, Data Science, and Microbiome Research
$1,000,000 – PI: W Xu, L Siu, B Haibe-Kains, B Coburn
2018-2020 CCC, Crohn’s and Colitis Canada
The Crohn’s and Colitis Canada GEM Project
$4,000,000 – PI: - K Croitoru; Co-I - W Xu
2017-2022 CIHR, Canadian Institutes of Health Research
Seeking Molecular Signatures for Nasopharyngeal Carcinoma
$1,147,500 – PI –F Liu; Co-I – W Xu
2017-2021 OICR, Ontario Institute for Cancer Research
Ovarian Cancer Translational Research Initiative
$10,000,000 – PI –A Oza, R Rottapel; Co-I – W Xu
2017-2022 NSERC, Natural Sciences and Engineering Research Council of Canada
Methodology Development and Implementation for Microbiome Sequencing Data: Hierarchical Modeling on Clustered Taxa Counts with Repeated Measures
$140,000 – PI –W Xu
2016-2018 CCSRI, Canadian Cancer Society Research Institute
Early detection of tumour response for adaptive therapy in oropharynx cancer
$200,000 – PI –S Bratman; Co-I – W Xu, F Liu, J Waldron, T Pugh
2016-2018 CIHR, Canadian Institutes of Health Research
X-chromosome wide genetic association on cancer prognostic and pharmacogenetic analysis of clinical trials: methodological development and analysis
$150,000 – PI –W Xu, G Liu; Co-I – R Hung, B Chen, C O’Callaghan
2016-2017 US DOD, Department of Defense
Identifying a reversible genetic factor that drives lung cancer in veteran African Americans to foster the early detection and prevention of lung cancer
$100,000 – PI –W Xu, D Reisman
2016-2017 Princess Margaret Cancer Foundation Invest in Research Grant
Impact of distinct HPV subtypes on survival in oropharyngeal cancer
$100,000 – PI – S Bratman; Co-I – W Xu, F Liu, J Bruce, T Pugh
2014-2016 McLaughlin Center Accelerator Grant
Early Detection of Lung Cancer Using Next Generation Sequencing Technology
$50,000 – PI –W Xu, G Liu; Co-I – R Hung, P Hu
2013-2014 OICR, Ontario Institute for Cancer Research
Pharmacokinetic and Pharmacogenetic analysis of NCIC CTG CO.20 and CO.17 Clinical Trials
$128,945 – PI –W Xu, G Liu; Co-I – E Morgen, LL Siu, X Chen, CJ O’Callaghan, A Brown, D Jonker, D Tu
2012-2015 CIHR, Canadian Institutes of Health Research
The Pharmacogenetics of Bevacizumab: A Companion Correlative Study of the Ovarian Cancer Clinical Trial, ICON7
$390,342 – PI – G Liu; Co-I – W Xu, R. Kim, H. MacKay, S
2012-2014 CCSRI, Canadian Cancer Society Research Institute
The relationship between local breast radiation with hematopoietic stem cell trafficking, and fatigue.
$198,320 – PI – FF Liu; Co-I – W Xu, M Li, M Minden,
Multivariate Association of Cardiovascular Disease Risk Factors in People with Type 1 diabetes, Fellowship Clinical Research Project. Funding Sources: 2016/9 - 2018/8, CIHR STAGE, Total Funding - 90,000 CAD
Travel Award 2017: Banting and Best Diabetes Center, 1000 CAD
Travel Award 2017: The Hospital for Sick Children, 1000 CAD
Travel Award 2016: Mc Laughlin Center, University of Toronto, 1000 CAD
CIHR STAGE (Strategic Training for Advanced Genetic Epidemiology) fellowship (2020-2022)
Funders
